CN101977626A - 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 - Google Patents

丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Download PDF

Info

Publication number
CN101977626A
CN101977626A CN2009801099736A CN200980109973A CN101977626A CN 101977626 A CN101977626 A CN 101977626A CN 2009801099736 A CN2009801099736 A CN 2009801099736A CN 200980109973 A CN200980109973 A CN 200980109973A CN 101977626 A CN101977626 A CN 101977626A
Authority
CN
China
Prior art keywords
serine protease
inhibitor
protease inhibitor
recombinant
kallikrein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801099736A
Other languages
English (en)
Chinese (zh)
Inventor
D·德佩尔特
C·昆丁
A·霍夫纳尼安
C·德雷松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Dermadis SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Dermadis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Dermadis SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201910841916.2A priority Critical patent/CN110522905A/zh
Publication of CN101977626A publication Critical patent/CN101977626A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
CN2009801099736A 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Pending CN101977626A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910841916.2A CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2238608P 2008-01-21 2008-01-21
US61/022,386 2008-01-21
US657608P 2008-01-22 2008-01-22
US61/006,576 2008-01-22
PCT/IB2009/000089 WO2009093119A2 (en) 2008-01-21 2009-01-21 Use of serine protease inhibitors in the treatment of skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910841916.2A Division CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Publications (1)

Publication Number Publication Date
CN101977626A true CN101977626A (zh) 2011-02-16

Family

ID=40901490

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801099736A Pending CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CN201910841916.2A Pending CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910841916.2A Pending CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Country Status (8)

Country Link
US (3) US20110130338A1 (enExample)
EP (1) EP2244728B1 (enExample)
JP (2) JP5615184B2 (enExample)
CN (2) CN101977626A (enExample)
AU (1) AU2009207394B2 (enExample)
BR (1) BRPI0906167A2 (enExample)
CA (1) CA2712512C (enExample)
WO (1) WO2009093119A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043861A1 (en) * 2012-09-19 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
CN106478812A (zh) * 2016-10-21 2017-03-08 沈阳药科大学 丝氨酸蛋白酶抑制剂‑3及其功能、制备方法和应用
CN106573155A (zh) * 2014-02-26 2017-04-19 鲁玛治疗公司 紫外光疗设备和方法
CN110114463A (zh) * 2016-11-23 2019-08-09 阿尔尼拉姆医药品有限公司 丝胺酸蛋白酶抑制剂A1 iRNA组合物及其使用方法
CN110330563A (zh) * 2013-12-13 2019-10-15 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN110536691A (zh) * 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 Klk5拮抗剂治疗疾病的用途
CN111050850A (zh) * 2017-06-16 2020-04-21 阿兹特拉公司 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130338A1 (en) 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
MX2011009272A (es) * 2009-03-10 2012-09-07 Med Discovery S A Uso de inhibidores de serina proteasa en el tratamiento de neutropenia.
KR101979464B1 (ko) 2011-12-09 2019-05-16 모멘티브 파포만스 마테리아루즈 쟈판 고도가이샤 실리콘 고무 발포체용 조성물, 실리콘 고무 발포체의 제조방법 및 실리콘 고무 발포체
TW201410709A (zh) * 2012-08-08 2014-03-16 Daiichi Sankyo Co Ltd 肽庫及其利用
KR101437408B1 (ko) 2012-11-05 2014-09-05 동아대학교 산학협력단 플라스민 및 엘라스타아제 저해 활성을 갖는 산왕거미 유래의 쿠니츠 타입 세린 프로테아제 저해 단백질 및 이를 유효성분으로 포함하는 염증 억제 및 항섬유소용해용 조성물
US10807805B2 (en) 2013-05-17 2020-10-20 Intelligrated Headquarters, Llc Robotic carton unloader
CN105473474B (zh) 2013-05-17 2018-01-23 因特利格兰特总部有限责任公司 机器人纸箱卸载机
WO2015114144A1 (en) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of netherton syndrome
JP6738280B2 (ja) * 2014-10-24 2020-08-12 株式会社 資生堂 角層剥離の抑制又は亢進に起因する肌状態を改善するための美容方法及び評価方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10597235B2 (en) 2016-10-20 2020-03-24 Intelligrated Headquarters, Llc Carton unloader tool for jam recovery
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
WO2021178752A1 (en) * 2020-03-06 2021-09-10 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
WO2023141125A2 (en) * 2022-01-18 2023-07-27 The Regents Of The University Of California Method of inhibiting degrading protease activity in aging
WO2024159008A1 (en) * 2023-01-25 2024-08-02 Quoin Pharmaceuticals, Inc. Combination treatment for netherton syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079336A (en) * 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5252725A (en) * 1989-06-23 1993-10-12 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
CA2377357C (en) * 1999-06-18 2013-07-23 Jon Bragi Bjarnason Fish serine proteinases and their pharmaceutical and cosmetic use
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
JP2004535758A (ja) * 2000-11-14 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー リンパ様細胞ｌｓｉ−０１から分泌される新規なヒトセルピンをコードするポリヌクレオチド
ATE439853T1 (de) * 2002-11-20 2009-09-15 Arriva Prometic Inc Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
US8975370B2 (en) * 2003-04-04 2015-03-10 Universite De Lausanne Inhibitor proteins of a protease and use thereof
WO2005117955A1 (en) * 2004-05-19 2005-12-15 Arriva Pharmaceuticals, Inc. Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
EP1666075A1 (en) * 2004-10-04 2006-06-07 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
CA2691849A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
EP2183270B1 (en) * 2007-08-17 2014-12-17 Novartis AG Use of cyclic depsipeptides to inhibit kallikrein 7
US20110130338A1 (en) * 2008-01-21 2011-06-02 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104903346A (zh) * 2012-09-19 2015-09-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
US9815878B2 (en) 2012-09-19 2017-11-14 Mackay Memorial Hospital Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
CN104903346B (zh) * 2012-09-19 2019-04-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
WO2014043861A1 (en) * 2012-09-19 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
CN110330563A (zh) * 2013-12-13 2019-10-15 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN110330563B (zh) * 2013-12-13 2024-03-29 剑桥实业有限公司 用于出血性疾病治疗的修饰的丝氨酸蛋白酶抑制剂
CN106573155A (zh) * 2014-02-26 2017-04-19 鲁玛治疗公司 紫外光疗设备和方法
CN106478812B (zh) * 2016-10-21 2020-11-20 沈阳药科大学 丝氨酸蛋白酶抑制剂-3及其功能、制备方法和应用
CN106478812A (zh) * 2016-10-21 2017-03-08 沈阳药科大学 丝氨酸蛋白酶抑制剂‑3及其功能、制备方法和应用
CN110114463A (zh) * 2016-11-23 2019-08-09 阿尔尼拉姆医药品有限公司 丝胺酸蛋白酶抑制剂A1 iRNA组合物及其使用方法
CN110536691A (zh) * 2017-04-21 2019-12-03 豪夫迈·罗氏有限公司 Klk5拮抗剂治疗疾病的用途
CN111050850A (zh) * 2017-06-16 2020-04-21 阿兹特拉公司 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法
CN114867865A (zh) * 2019-11-21 2022-08-05 密执安大学评议会 中性粒细胞弹性蛋白酶活性的多肽抑制剂及其用途
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用

Also Published As

Publication number Publication date
JP5891266B2 (ja) 2016-03-22
JP2011511766A (ja) 2011-04-14
BRPI0906167A2 (pt) 2018-05-22
CA2712512C (en) 2018-08-28
CA2712512A1 (en) 2009-07-30
EP2244728A2 (en) 2010-11-03
JP5615184B2 (ja) 2014-10-29
JP2014240389A (ja) 2014-12-25
CN110522905A (zh) 2019-12-03
WO2009093119A3 (en) 2009-11-26
AU2009207394B2 (en) 2015-01-22
AU2009207394A1 (en) 2009-07-30
US20140341881A1 (en) 2014-11-20
US20190183989A1 (en) 2019-06-20
US20110130338A1 (en) 2011-06-02
EP2244728B1 (en) 2016-08-31
US11793864B2 (en) 2023-10-24
WO2009093119A2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
CN101977626A (zh) 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
US20110104179A1 (en) Protease inhibitory peptides
US20140288007A1 (en) Gingipain inhibitory propeptides
KR101296367B1 (ko) 프로테아제 억제 단백질 및 그 이용
US9642898B2 (en) Use of serine protease inhibitors in the treatment of neutropenia
JP2006254875A (ja) 不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法
HK1151236A (en) Use of serine protease inhibitors in the treatment of skin diseases
ES2604215T3 (es) Uso de inhibidores de serina proteasas en el tratamiento de enfermedades de la piel
Diamandis et al. Induction of Complement C3a Receptor
Jayakumar et al. Molecular and biochemical properties of lympho-epithelial kazal-type-inhibitor (LEKTI)
Valueva et al. A novel human leukocyte elastase inhibitor from duck egg white

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151236

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110216

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1151236

Country of ref document: HK